Par Health Launches First Janumet XR Generic
Par Health Janumet XR generic launch brings the first FDA-approved sitagliptin/metformin extended-release copy of Merck's brand to U.S. pharmacies. Par said on July 24, 2026 that final ANDA approval cleared a first-to-market entry against a product with about $270 million in trailing U.S. sales.
Contents9 sections
Key Takeaways
- Par Health launched the first and only FDA-approved generic of Janumet XR in the United States.
- Approval path was a final Abbreviated New Drug Application (ANDA).
- IQVIA data cited by Par put brand U.S. sales near $269.9 million for the 12 months ended May 2026.
- Full prescribing information includes a Boxed Warning; label risks track the reference product.
Janumet XR generic at a glance
| Field | Detail |
|---|---|
| Product | Sitagliptin and metformin HCl extended-release tablets (generic Janumet XR) |
| Company | Par Health, Inc. |
| Reference brand | Merck Sharp & Dohme Janumet XR |
| FDA path | Final ANDA approval; U.S. launch July 24, 2026 |
| Market size cited | ~$269.9M U.S. sales (IQVIA, 12 months ended May 2026) |
| Status claim | First and only FDA-approved Janumet XR generic available (company) |
What did Par announce?
Par Health said it launched an oral generic of Janumet XR after the FDA granted final ANDA approval. The company framed the entry as expanding access to a DPP-4 inhibitor / metformin XR fixed-dose combination used in type 2 diabetes care.
Source: Par Health's July 24 PR Newswire launch release.
Why does first generic entry matter?
Brand Janumet XR had nearly $270 million in estimated annual U.S. sales on the IQVIA cut Par cited. First-to-market generics often capture early share before additional ANDA holders enter. Jake Longenecker, Par's generics commercial lead, said the launch strengthens the company's essential-medicines portfolio.
FDA's generic-drug framework and Orange Book listings are explained on FDA's generic drugs overview.
What should clinicians and pharmacists watch?
- Confirm strength and dosing against the reference label
- Review the Boxed Warning and metformin lactic-acidosis precautions
- Check renal dosing limits and sitagliptin hypersensitivity warnings
- Monitor supply continuity as the sole generic at launch
DailyMed / labeling resources for metformin combination products are hosted via NLM DailyMed. For type 2 diabetes care teams, a first generic of a sitagliptin/metformin XR fixed dose can simplify prior-authorization conversations when brand-only coverage was the barrier, but therapeutic interchange still depends on the exact tablet strengths stocked and on whether a patient’s current regimen matches an available SKU.
Patients switching from brand to generic should be counseled that the active ingredients and labeled risks are the same class of product, while tablet appearance and inactive ingredients may differ. Pharmacies should also confirm that extended-release handling instructions (for example, not crushing XR tablets) remain clear at the point of dispensing.
What remains uncertain?
Par did not disclose SKU strengths launched, WAC pricing, or wholesale distribution partners. "Only" status can change quickly as additional ANDAs clear. Real-world substitution rates depend on state pharmacy law and payer macros.
Related NovaPharma coverage
- FDA expands Tzield to certain pediatric Stage 3 T1D
- FDA approves Merck oral PCSK9 drug
- Compounded GLP-1s Why doctors worry and FDA acts
Frequently Asked Questions
What generic did Par Health launch?
On July 24, 2026, Par Health said it launched its generic version of Merck's Janumet XR (sitagliptin and metformin HCl extended-release) tablets after final FDA approval of its Abbreviated New Drug Application. The company called it the first and only FDA-approved Janumet XR generic available in the U.S.
How large is the Janumet XR U.S. market Par cited?
Par Health cited IQVIA data estimating about $269.9 million in annual U.S. Janumet XR sales for the 12 months ended May 2026.
What safety information applies?
Par directed readers to the full prescribing information, including a Boxed Warning. Sitagliptin/metformin XR products carry metformin-related lactic acidosis warnings and other labeled risks that apply to the generic as well as the brand.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for sitagliptin.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
